JP2013516489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516489A5 JP2013516489A5 JP2012548193A JP2012548193A JP2013516489A5 JP 2013516489 A5 JP2013516489 A5 JP 2013516489A5 JP 2012548193 A JP2012548193 A JP 2012548193A JP 2012548193 A JP2012548193 A JP 2012548193A JP 2013516489 A5 JP2013516489 A5 JP 2013516489A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- modified
- composition according
- compound
- modified oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 108091034117 Oligonucleotide Proteins 0.000 claims 13
- 239000002777 nucleoside Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 6
- 125000003835 nucleoside group Chemical group 0.000 claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 4
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 claims 4
- 230000002503 metabolic effect Effects 0.000 claims 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29360410P | 2010-01-08 | 2010-01-08 | |
| US61/293,604 | 2010-01-08 | ||
| PCT/US2011/020606 WO2011085271A2 (en) | 2010-01-08 | 2011-01-07 | Modulation of angiopoietin-like 3 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015156939A Division JP6440592B2 (ja) | 2010-01-08 | 2015-08-07 | アンジオポエチン様３発現の調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516489A JP2013516489A (ja) | 2013-05-13 |
| JP2013516489A5 true JP2013516489A5 (enExample) | 2013-08-08 |
| JP5822845B2 JP5822845B2 (ja) | 2015-11-25 |
Family
ID=44306180
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548193A Expired - Fee Related JP5822845B2 (ja) | 2010-01-08 | 2011-01-07 | アンジオポエチン様３発現の調節 |
| JP2015156939A Expired - Fee Related JP6440592B2 (ja) | 2010-01-08 | 2015-08-07 | アンジオポエチン様３発現の調節 |
| JP2017098842A Pending JP2017165765A (ja) | 2010-01-08 | 2017-05-18 | アンジオポエチン様３発現の調節 |
| JP2020032712A Pending JP2020100654A (ja) | 2010-01-08 | 2020-02-28 | アンジオポエチン様３発現の調節 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015156939A Expired - Fee Related JP6440592B2 (ja) | 2010-01-08 | 2015-08-07 | アンジオポエチン様３発現の調節 |
| JP2017098842A Pending JP2017165765A (ja) | 2010-01-08 | 2017-05-18 | アンジオポエチン様３発現の調節 |
| JP2020032712A Pending JP2020100654A (ja) | 2010-01-08 | 2020-02-28 | アンジオポエチン様３発現の調節 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US8653047B2 (enExample) |
| EP (2) | EP2521556B1 (enExample) |
| JP (4) | JP5822845B2 (enExample) |
| CN (3) | CN106146591B (enExample) |
| AU (1) | AU2011203986C1 (enExample) |
| CA (1) | CA2786071C (enExample) |
| DK (1) | DK2521556T3 (enExample) |
| ES (1) | ES2677969T3 (enExample) |
| WO (1) | WO2011085271A2 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| EP2521556B1 (en) * | 2010-01-08 | 2018-05-30 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| CN103890000B (zh) | 2011-06-21 | 2017-09-01 | 阿尔尼拉姆医药品有限公司 | 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法 |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| US9725722B2 (en) | 2011-11-07 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | Modulation of TMPRSS6 expression |
| HK1200191A1 (en) * | 2011-11-18 | 2015-07-31 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
| SG11201500243WA (en) | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| KR20240148947A (ko) | 2012-07-13 | 2024-10-11 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| JP6452614B2 (ja) | 2012-11-15 | 2019-01-16 | ロシュ イノベーション センター コペンハーゲン エーエス | オリゴヌクレオチドコンジュゲート |
| DK2951305T3 (en) | 2013-01-30 | 2018-10-29 | Hoffmann La Roche | LNA oligonucleotide KULHYDRATKONJUGATER |
| PE20152002A1 (es) | 2013-05-01 | 2016-01-21 | Isis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de ttr y vhb |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| CN105814204B (zh) * | 2013-12-24 | 2020-04-28 | Ionis制药公司 | 促血管生成素样3表达的调节 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| ES2844593T3 (es) * | 2014-05-01 | 2021-07-22 | Ionis Pharmaceuticals Inc | Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3 |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| US20180245077A1 (en) * | 2015-03-20 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
| WO2016161429A1 (en) | 2015-04-03 | 2016-10-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating tmprss6 expression |
| KR20250005546A (ko) * | 2015-04-13 | 2025-01-09 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오포이에틴-유사 3(angptl3) irna 조성물 및 이의 이용 방법 |
| RU2018120599A (ru) * | 2015-11-06 | 2019-12-09 | Джемфир Терапьютикс, Инк. | Лечение смешанной дислипидемии |
| HRP20241087T1 (hr) | 2015-11-06 | 2024-11-08 | Ionis Pharmaceuticals, Inc. | Konjugirani protusmisleni spojevi za upotrebu u terapiji |
| KR20250078597A (ko) | 2015-11-06 | 2025-06-02 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포리포프로테인 (a) 발현 조정 |
| ES2951262T3 (es) * | 2016-02-17 | 2023-10-19 | Regeneron Pharma | Métodos para tratar o prevenir la aterosclerosis mediante la administración de un inhibidor de ANGPTL3 |
| KR102456731B1 (ko) | 2016-03-03 | 2022-10-24 | 리제너론 파아마슈티컬스, 인크. | Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법 |
| US10961271B2 (en) * | 2016-03-16 | 2021-03-30 | Ionis Pharmaceuticals, Inc. | Methods of modulating KEAP1 |
| CA3021884A1 (en) * | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with familial hypercholesterolemia |
| US11390867B2 (en) | 2016-04-29 | 2022-07-19 | Nanyang Technological University | G-quadruplex-containing antisense oligonucleotides |
| CN109477103A (zh) | 2016-06-22 | 2019-03-15 | ProQR治疗上市公司Ⅱ | 单链rna-编辑寡核苷酸 |
| EP3507366B1 (en) | 2016-09-01 | 2020-10-07 | ProQR Therapeutics II B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| CN113652431A (zh) * | 2016-12-21 | 2021-11-16 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| EP3571300A1 (en) | 2017-01-19 | 2019-11-27 | ProQR Therapeutics II B.V. | Oligonucleotide complexes for use in rna editing |
| US11677246B2 (en) | 2017-08-30 | 2023-06-13 | Kyocera Corporation | Power management method and power management apparatus |
| AU2018331383B2 (en) * | 2017-09-14 | 2024-12-05 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| WO2019105418A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| KR20250107294A (ko) | 2017-12-01 | 2025-07-11 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도 |
| JP7273417B2 (ja) | 2017-12-01 | 2023-05-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| DK3732185T3 (da) | 2017-12-29 | 2025-03-31 | Suzhou Ribo Life Science Co Ltd | Konjugater og fremstilling og anvendelse heraf |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| EP3842534A4 (en) | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE |
| WO2020063198A1 (zh) | 2018-09-30 | 2020-04-02 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| KR20210090660A (ko) * | 2018-11-13 | 2021-07-20 | 리피곤 파마슈티컬스 에이비 | 지방산 대사의 조절에 영향을 미치는 angptl4 올리고뉴클레오타이드 |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN112423795A (zh) * | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2020146477A1 (en) * | 2019-01-08 | 2020-07-16 | Avogadro Development Corp. | Treatment of fatty liver disease |
| CA3139195A1 (en) | 2019-05-22 | 2020-11-26 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| EP3974530A4 (en) | 2019-05-22 | 2023-07-12 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD OF MANUFACTURE AND USE |
| CN111973617A (zh) * | 2019-05-23 | 2020-11-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610849B2 (ja) | 2019-05-24 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| CN115516092B (zh) * | 2020-09-30 | 2025-05-16 | 亿腾医药（苏州）有限公司 | 血管生成素样3(ANGPTL3)的siRNA及其用途 |
| IL305418A (en) | 2021-03-04 | 2023-10-01 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them |
| KR20240023635A (ko) * | 2021-06-21 | 2024-02-22 | 상하이 준스 바이오사이언스 컴퍼니 리미티드 | ANGPTL3 유전자 발현을 억제하는 siRNA 및 이의 용도 |
| US20230193271A1 (en) | 2021-12-22 | 2023-06-22 | Regeneron Pharmaceuticals, Inc. | Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors |
| WO2023134705A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海金中锘美生物医药科技有限公司 | 抑制angptl3表达的rna干扰剂及其用途 |
| CN119585431A (zh) * | 2022-08-08 | 2025-03-07 | 大睿生物医药科技(上海)有限公司 | 调控ANGPTL3基因活性的siRNA分子 |
| AU2023375521A1 (en) | 2022-11-10 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| EP0673559A1 (en) | 1992-12-14 | 1995-09-27 | Honeywell Inc. | Motor system with individually controlled redundant windings |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| NZ509739A (en) * | 1998-09-15 | 2003-10-31 | Btg Int Ltd | A cyclic ester of (R)-3-hydroxybutyrate useful for increasing cardiac efficiency |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| EP1210363A2 (en) * | 1999-07-16 | 2002-06-05 | Hyseq, Inc. | Novel angiopoietin materials and methods |
| CN1433482A (zh) * | 1999-12-09 | 2003-07-30 | 三共株式会社 | 高脂血症的治疗或预防剂的检验方法 |
| CA2450022A1 (en) | 2001-06-08 | 2002-12-19 | Sankyo Company, Limited | Method of testing drug for treating or preventing diseases such as hyperlipemia |
| CA2452458A1 (en) * | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| EP1451578B1 (en) | 2001-11-16 | 2013-08-21 | Genentech, Inc. | Use of angptl3 antagonists for the treatment of liver diseases |
| EP1562971B1 (en) | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| AU2003295387A1 (en) | 2002-11-05 | 2004-06-03 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| WO2004072046A2 (en) | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivatives and their use for modulation of lxr activity |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| US20110086342A1 (en) | 2003-08-22 | 2011-04-14 | Nihon University | Hepatocellular Carcinoma-Associated Gene |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| AU2004274021B2 (en) | 2003-09-18 | 2009-08-13 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
| US7468431B2 (en) * | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
| EP1735622A2 (en) * | 2004-04-13 | 2006-12-27 | Arena Pharmaceuticals, Inc. | Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders |
| AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| PT1771474E (pt) | 2004-07-20 | 2010-05-03 | Genentech Inc | Inibidores de proteína 4 do tipo angiopoietina, combinações e sua utilização |
| US7371384B2 (en) * | 2004-07-20 | 2008-05-13 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein antibody |
| EP2397563A3 (en) | 2004-09-17 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| US20060147894A1 (en) | 2004-12-30 | 2006-07-06 | Vicam, L.P. | Jacketed vessel for holding semen for sex biasing mammals through artificial insemination and systems and methods for enhancing the probability of sex biasing using the same |
| CA2640171C (en) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| CA3044969A1 (en) | 2006-05-05 | 2007-12-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
| JP5441688B2 (ja) | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ， インコーポレーテッド | ５’修飾二環式核酸類似体 |
| US8101585B2 (en) * | 2006-08-04 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of JNK proteins |
| US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| CN101589143A (zh) * | 2006-11-27 | 2009-11-25 | Isis药物公司 | 用于治疗高胆固醇血症的方法 |
| CN101855241B (zh) | 2006-12-08 | 2013-11-06 | 莱克康制药公司 | 针对angptl3的单克隆抗体 |
| WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| CA2717618A1 (en) | 2008-03-07 | 2009-09-11 | National University Corporation University Of Toyama | Homologous recombination method, cloning method, and kit |
| JP5207355B2 (ja) | 2008-03-12 | 2013-06-12 | 凸版印刷株式会社 | 標的ヌクレオチド配列を有する核酸の検出方法、プローブセット、及び核酸の識別方法 |
| WO2009148605A2 (en) | 2008-06-04 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| EP2521556B1 (en) | 2010-01-08 | 2018-05-30 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| EP2733390B1 (en) | 2012-11-15 | 2020-05-13 | Volvo Car Corporation | Dampening structure for gear shift cables |
| US10120707B2 (en) | 2015-12-08 | 2018-11-06 | Paypal, Inc. | Deployment of development environments |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2011
- 2011-01-07 EP EP11732249.5A patent/EP2521556B1/en active Active
- 2011-01-07 JP JP2012548193A patent/JP5822845B2/ja not_active Expired - Fee Related
- 2011-01-07 CN CN201610643333.5A patent/CN106146591B/zh not_active Expired - Fee Related
- 2011-01-07 DK DK11732249.5T patent/DK2521556T3/en active
- 2011-01-07 US US13/520,997 patent/US8653047B2/en active Active
- 2011-01-07 EP EP18174926.8A patent/EP3421040A1/en not_active Withdrawn
- 2011-01-07 AU AU2011203986A patent/AU2011203986C1/en not_active Ceased
- 2011-01-07 CN CN201180008657.7A patent/CN102753186B/zh not_active Expired - Fee Related
- 2011-01-07 CA CA2786071A patent/CA2786071C/en active Active
- 2011-01-07 CN CN202010636959.XA patent/CN111700901A/zh active Pending
- 2011-01-07 WO PCT/US2011/020606 patent/WO2011085271A2/en not_active Ceased
- 2011-01-07 ES ES11732249.5T patent/ES2677969T3/es active Active
-
2014
- 2014-01-07 US US14/149,715 patent/US9139831B2/en active Active
-
2015
- 2015-08-07 JP JP2015156939A patent/JP6440592B2/ja not_active Expired - Fee Related
- 2015-08-10 US US14/821,982 patent/US20160060626A1/en not_active Abandoned
-
2017
- 2017-05-18 JP JP2017098842A patent/JP2017165765A/ja active Pending
-
2018
- 2018-01-12 US US15/870,306 patent/US20180142244A1/en not_active Abandoned
-
2019
- 2019-12-20 US US16/722,043 patent/US11225664B2/en active Active
-
2020
- 2020-02-28 JP JP2020032712A patent/JP2020100654A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516489A5 (enExample) | ||
| JP2012029693A5 (enExample) | ||
| JP2014513954A5 (enExample) | ||
| JP2013518605A5 (enExample) | ||
| Tian et al. | Brahma‐related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice | |
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| Thum et al. | MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts | |
| IL264288B (en) | Methods and compositions for modulating apolipoprotein(a) expression | |
| JP2017533721A5 (enExample) | ||
| HRP20210244T1 (hr) | Moduliranje eksprimiranja virusa hepatitisa b (hbv) | |
| JP2015536132A5 (enExample) | ||
| NO2019001I1 (no) | Forbindelse omfattende et modifisert oligonukleotid som har en nukleobasesekvens bestående av 20 koblede nukleosider ifølge EP B1 2563920 krav 1 (SEQ ID NO: 80), hvor det modifiserte oligonukleotidet omfatter: et avstandssegment bestående av ti koblede deoksynukleosider; et 5'-vingesegment bestående av fem koblede nukleosider; og et 3'-vingesegment bestående av fem koblede nukleosider; hvor avstandssegmentet er plassert mellom 5'-vingesegmentet og 3'-vingesegmentet, hvor hvert nukleosid av hvert vingesegment omfatter et 2'-0-metoksyetylsukker; hvor hver cytosin av det modifiserte oligonukleotid er en 5-metylcytosin, og hvor hver internukleosid-binding av det modifiserte oligonukleotid er en fosfortioatbinding; og spesielt inotersen; og dets derivater, så som dets salter, inkludert natriumsalter. | |
| JP2016501513A5 (enExample) | ||
| JP2013226147A5 (enExample) | ||
| HRP20241138T1 (hr) | Oligonukleotidi za induciranje ekspresije očinskog ube3a | |
| JP2015507625A5 (enExample) | ||
| JP2012050438A5 (enExample) | ||
| IL264241A (en) | Compositions and methods for modulating hbv and ttr expression | |
| JP2009508527A5 (enExample) | ||
| JP2017509354A5 (enExample) | ||
| HRP20130766T1 (hr) | Mikrornk (mirnk) mir-21 za dijagnostiäśke i terapijske svrhe | |
| Van Gestel et al. | shRNA-induced saturation of the microRNA pathway in the rat brain | |
| RU2011119479A (ru) | Модуляция экспрессии фактора 11 | |
| JP2016526018A5 (enExample) | ||
| JP2012527444A5 (enExample) |